These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3241383)

  • 1. [Progress on complement protein chemistry and the molecular mechanism of activation. Alternative complement pathway].
    Kinoshita T
    Nihon Rinsho; 1988 Sep; 46(9):1894-8. PubMed ID: 3241383
    [No Abstract]   [Full Text] [Related]  

  • 2. The human alternative complement pathway: biology and immunopathology of activation and regulation.
    Kazatchkine MD; Nydegger UE
    Prog Allergy; 1982; 30():193-234. PubMed ID: 7041132
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
    [No Abstract]   [Full Text] [Related]  

  • 4. Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection.
    Fearon DT; Austen KF
    N Engl J Med; 1980 Jul; 303(5):259-63. PubMed ID: 6900901
    [No Abstract]   [Full Text] [Related]  

  • 5. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
    Sobel AT; Cooper NR; Schreiber RD
    J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of C3 nephritic factor on the complement system--with special reference to stabilizing effect on C3 convertase (C3bBb) activity (author's transl)].
    Nakanishi I
    Nihon Jinzo Gakkai Shi; 1981 Jun; 23(6):719-32. PubMed ID: 6914399
    [No Abstract]   [Full Text] [Related]  

  • 7. [Progress in the knowledge of complement. I. Structure, activation and control of the complement system].
    Lesavre P; Leibowitch J
    Nouv Presse Med; 1979 Jun; 8(29):2385-7. PubMed ID: 493022
    [No Abstract]   [Full Text] [Related]  

  • 8. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
    Kazatchkine MD; Fearon DT; Austen KF
    J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425
    [No Abstract]   [Full Text] [Related]  

  • 10. [Progress in the knowledge of complement. II. Nephritic factors].
    Leibowitch J; Lesavre P
    Nouv Presse Med; 1979 Jul; 8(30):2447-8. PubMed ID: 493036
    [No Abstract]   [Full Text] [Related]  

  • 11. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The alternative complement pathway].
    Jouvin MH; Kazatchkine M
    Pathol Biol (Paris); 1983 Dec; 31(10):839-46. PubMed ID: 6230588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-specific immune mechanisms. The alternate pathway in the complement system].
    Schön K; Koeppe HW
    Med Klin; 1979 Mar; 74(13):461-9. PubMed ID: 431472
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Structure and function of alternative pathway components of complement].
    Tomita M; Sugita Y
    Tanpakushitsu Kakusan Koso; 1986 Jul; 31(9 Suppl):847-64. PubMed ID: 3641329
    [No Abstract]   [Full Text] [Related]  

  • 16. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets.
    Ekdahl KN; Nilsson B
    J Immunol; 1999 Jun; 162(12):7426-33. PubMed ID: 10358196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.
    Fischer E; Ouaissi MA; Velge P; Cornette J; Kazatchkine MD
    Immunology; 1988 Oct; 65(2):299-303. PubMed ID: 2973433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual function of insoluble polyanions. Formation of C1 and C42 sites in addition to activation of the alternative pathway of complement.
    Burger R; Loos M; Kossorotow A; Hadding U; Bitter-Suermann D
    Monogr Allergy; 1977; 12():78-81. PubMed ID: 917023
    [No Abstract]   [Full Text] [Related]  

  • 19. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5.
    Strunk RC; Giclas PC
    J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular biology and chemistry of the alternative pathway of complement.
    Müller-Eberhard HJ; Schreiber RD
    Adv Immunol; 1980; 29():1-53. PubMed ID: 6158260
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.